## Jing Geng

## List of Publications by Year in descending order

Source: https:/|exaly.com/author-pdf/8180441/publications.pdf
Version: 2024-02-01


Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase. Laboratory
Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases. Molecular Therapy, 2021, 29,$7 \quad$ Targeting FSTL1 for Multiple Fibrotic and Systemic Autoimmune Diseases. Molecular Therapy, 2021, 29,
$8.2 \quad 18$
$8 \quad$ Fatty Acid Metabolism and Idiopathic Pulmonary Fibrosis. Frontiers in Physiology, 2021, 12, 794629.

Physiology, 2019, 104, 1942-1951.

10 Pulmonary fibrosis in a mouse model of sarcoid granulomatosis induced by booster challenge with
<i>Propionibacterium acnes</i>. Oncotarget, 2016, 7, 33703-33714.
1.8

16
11 Modeling alveolar injury using microfluidic co-cultures for monitoring bleomycin-inducedepithelial/fibroblastic cross-talk disorder. RSC Advances, 2017, 7, 42738-42749.Spectrum of interstitial lung disease in China from 2000 to 2012. European Respiratory Journal, 2018,52, 1701554.
6.7

142.413Biology and Medicine, 2016, 241, 157-165.14 Krebs von den Lungenâ€6 levels in untreated idiopathic pulmonary fibrosis. Clinical Respiratory Journal,

